Why the study?
Whether the absolute risk-benefit favors anticoagulation in patients with only device-detected atrial fibrillation who lack clinically documented atrial fibrillation remains unclear.
Does therapeutic anticoagulation reduce ischemic stroke risk without excessive bleeding in patients with device-detected subclinical AF?
Population
Patients with device-detected subclinical atrial fibrillation (AF) or atrial high-rate episodes
Design
Editorial
Key result
The absolute risk-benefit of therapeutic anticoagulation in patients with only device-detected atrial fibrillation remains unclear due to lower absolute rates of ischemic stroke and bleeding risks.
Authors
Loading...
Device-detected subclinical AF episodes complicate risk stratification; leaves open anticoagulation thresholds for short-duration events.
Does therapeutic anticoagulation reduce ischemic stroke risk without excessive bleeding in patients with device-detected subclinical AF?
The optimal management of subclinical device-detected AF remains uncertain, as the lower absolute risk of stroke must be weighed against the bleeding risks of anticoagulation.
Patel et al. (2024) conducted a review in Subclinical Atrial Fibrillation. Anticoagulation was evaluated. The absolute risk-benefit of therapeutic anticoagulation in patients with only device-detected atrial fibrillation remains unclear due to lower absolute rates of ischemic stroke and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: